This study focuses on patients who have locally advanced head and neck cancer. The purpose of the study is to determine whether cisplatin (chemotherapy drug) given weekly with radiation has fewer side effects than cisplatin given every 3 weeks with radiation. Additionally, researchers want to learn whether cisplatin given weekly with radiation can extend the patient’s life by at least the same amount of time as cisplatin given every 3 weeks with radiation.
The usual approach for patients who are not in this study is treatment with radiation therapy combined with cisplatin. Cisplatin is approved by the U.S. Food and Drug Administration (FDA) to treat head and neck cancer. Participants will receive either radiation for 7 weeks and high-dose cisplatin every 3 weeks for up to 7 weeks, or radiation for 7 weeks and low-dose cisplatin weekly for up to 7 weeks.
What is the full name of this clinical trial?
NRG-HN009: Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck ,